Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBerate-FH: LIB003 in Heterozygous Familial Hypercholesterolemia
NCT04797104Phase 3Completed
- Sponsor
- LIB Therapeutics
- Start
- Apr 2021
- Primary completion
- Jul 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 5
01
Overview
A Phase 3 trial of lerodalcibep in heterozygous familial hypercholesterolemia (HeFH), sponsored by LIB Therapeutics. Started Apr 2021; status: completed.
02
Drugs
lerodalcibep
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT04797104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04797104.